Sodium fluoride PET/CT can detect bone metastases in prostate cancer patients

June 8, 2016

Sodium fluoride (Na-F-18) PET/CT can accurately detect bone metastases in patients with advanced prostate cancer, according to a new pilot study published in The Journal of Nuclear Medicine. Follow-up scans revealed that it's also associated with better clinical outcomes and patient survival.

The American Cancer Society estimates that there will be about 180,890 new cases of prostate cancer and about 26,120 deaths from the disease in the U.S. this year.

The researchers had 30 prostate cancer patients with, and 30 without known bone metastases, using conventional imaging, undergo Na-F-18 PET/CT exams at a 6-month and then 20-month interval. 

...“Our study suggests that NaF-PET/CT may be a useful imaging modality in the diagnosis, prognosis and follow-up of prostate cancer patients at high risk for bone metastasis," Dr. Andrea B. Apolo of the National Cancer Institute, said in a statement. "It provides a strong rationale to further the clinical development of NaF-PET/CT as a bone imaging tool in prostate cancer and other malignancies."

Read the full article.